The global lung cancer therapeutics market share is projected to reach US$ 48,725.9 Million by 2026, exhibiting a CAGR of 13.4% in the forecast period.
Lung cancer diagnoses have increased as a result of increased cancer awareness in both advanced and emerging economies, as well as the introduction of new medical diagnostic equipment and improved treatments, propelling the lung cancer therapeutics market forward.
This, along with increased spending in research and innovation by leading players, is fueling the demand for lung cancer therapeutics. The shift in the market is mostly due to a higher focus on research projects as a result of the rising incidence of lung cancer.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2026) | US$ 48,725.9 Million |
| Projected Growth Rate (2022 to 2032) | 13.4% CAGR |
The worldwide lung cancer therapeutics market is predicted to grow at a high rate as the incidence of lung cancer rises. The global lung cancer therapeutics market is being driven by a growing demand for tailored therapy, the availability of highly effective medications, an increase in the elderly population, and an increase in the prevalence of unhealthy lifestyles.
The introduction of nanomedicine to treat lung cancer and the growing number of approvals in the lung cancer treatments market are driving the demand for lung cancer therapeutics.
With rising regulatory approvals and the acceptance of modern treatments in Europe, the lung cancer therapeutics market is predicted to develop.
In growing economies such as China and India, however, the surge in lung disease prevalence and the dominance of chemotherapy are driving the growth of the lung cancer therapeutics market. Advanced immunotherapies and tailored medicines are becoming more expensive in countries like Japan, thus limiting the demand for lung cancer therapeutics.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Lung cancer is a malignant tumor characterized by the uncontrolled growth of cell tissues in the lung. It is the second most commonly diagnosed and has the highest mortality rate of all cancers in both men and women. Thus, with the rise in the incidence rate of lung cancer, the demand for lung cancer therapeutics is also expected to grow during the study period.
Increasing incidences of lung cancer due to the rising smoking population is one of the major factors driving the growth of the lung cancer therapeutics market. The risk of lung cancer is tenfold higher in smokers as compared to non-smokers.
The launch of premium-priced drugs and new innovative radiation therapies coupled with rising incidences of NSCLC is the major driving factors for the growth of the lung cancer therapeutics market. However, the generalization of the major drugs might restrict the demand for lung cancer therapeutics.
Based on the cancer cell types, lung cancer is broadly segmented as small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC segment accounts for approximately 80 to 90% of all lung cancers.
Based on the cell shape and size, NSCLC is further divided into three subtypes they are adenocarcinoma, large-cell carcinoma, and squamous cell carcinoma. These NSCLCs are primarily treated with surgeries. At the same time, chemotherapy is increasingly used for both the pre-operative and post-operative treatment of patients.
The treatment options available for the NSCLC include surgery, radiation therapy, and chemotherapy. The top five global brands that are commercially available in the market are Avastin, Tarceva, Alimta, Gemzar, and Taxotere. Thus, all the above-mentioned factors collectively drive the growth of the global lung cancer therapeutics market.
Principal Consultant
Geographically, North America and Europe dominate the global lung cancer therapeutics market. According to Lung Disease Research Funding, approximately 75,000 people in the USA die because of lung injury every year.
The USA is the largest market for NSCLC owing to the high incidence rate rise in the aging population. In addition, with the advent of new treatment therapies such as targeted drug therapy, stereotactic are aiding the growth of the lung cancer therapeutics market share.
Europe accounts for the highest demand for lung cancer therapeutics after North America. At the same time, Asia-Pacific countries such as India and China, and South East Asia are the emerging regions for the global lung cancer therapeutics market due to the high prevalence of this disease coupled with increasing healthcare awareness.
Players are adopting various strategies to expand their product portfolio and increase their geographical presence for demand for lung cancer therapeutics. Some of the key strategies used by players in the global lung cancer therapeutics market include product innovation, partnerships and alliances, and mergers.
The prominent leading players of driving the lung cancer therapeutics market share include AstraZeneca Lc, Eli Lilly, and Company, GlaxoSmithKline, Hoffman-La Roche, Boehringer Ingelheim GmbH, Pfizer Inc., and Sanofi-Aventis, among others.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Report Attributes | Details |
|---|---|
| Growth rate | CAGR of 13.4% from 2022 to 2030 |
| The base year for estimation | 2021 |
| Historical data | 2015 to 2020 |
| Forecast period | 2022 to 2032 |
| Quantitative units | Revenue in USD Million, volume in kilotons, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis, |
| Segments Covered | Product, application, region |
| Regional scope | North America; Western Europe; Eastern Europe; Middle East; Africa; ASEAN; South Asia; Rest of Asia |
| Country scope | USA, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, United Arab Emirates(UAE), Iran, South Africa |
| Key companies profiled | AstrazenecaPlc; Sanofi-Aventis.; GlaxoSmitKline; Eli Lilly and Company; BoehringerIngelheim GmbH; Pfizer Inc.; Hoffman-La Roche |
| Customization scope | Free report customization (equivalent to up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
Targeted therapy is the leading segment in the lung cancer therapeutics market.
Demand for lung cancer therapeutics is projected to advance at a CAGR of 13.4% during the forecast period.
North America has the highest lung cancer therapeutics market share.
1. Executive Summary | Lung Cancer Therapeutics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. Value Chain Analysis 3.5.1. Profit Margin Analysis 3.5.2. Service Providers 3.6. PESTLE and Porter's Analysis 3.7. Regulatory Landscape 3.7.1. By Key Regions 3.7.2. By Key Countries 3.8. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Treatment Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2022 to 2032 5.3.1. Chemotherapy 5.3.2. Targeted Therapy 5.3.3. Radiotherapy 5.3.4. Biological Therapy 5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Treatment Type, 2022 to 2032 Deep-dive segmentation will be available in the sample on request 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Disease Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2022 to 2032 6.3.1. Non-small Cell Lung Cancer (NSCLC) 6.3.2. Small Cell Lung Cancer (SCLC) 6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By Disease Type, 2022 to 2032 Deep-dive segmentation will be available in the sample on request 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Class 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2017 to 2021 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2022 to 2032 7.3.1. Immunosuppressant 7.3.2. Monoclonal Antibodies 7.3.3. Tyrosine Kinase 7.3.4. Epidermal Growth Factors Receptors 7.3.5. Topoisomerase Inhibitors 7.3.6. Others 7.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017 to 2021 7.5. Absolute $ Opportunity Analysis By Drug Class, 2022 to 2032 Deep-dive segmentation will be available in the sample on request 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Route of Administration 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2017 to 2021 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2022 to 2032 8.3.1. Oral 8.3.2. Injectable 8.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017 to 2021 8.5. Absolute $ Opportunity Analysis By Route of Administration, 2022 to 2032 Deep-dive segmentation will be available in the sample on request 9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel 9.1. Introduction / Key Findings 9.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2017 to 2021 9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2022 to 2032 9.3.1. Hospital 9.3.2. Specialty Clinics 9.3.3. Clinical Research Institutes 9.3.4. Home Care Settings 9.3.5. Ambulatory Surgical Centers 9.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2021 9.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022 to 2032 Deep-dive segmentation will be available in the sample on request 10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 10.1. Introduction 10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021 10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. East Asia 10.3.5. South Asia & Pacific 10.3.6. Middle East and Africa 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. USA 11.2.1.2. Canada 11.2.2. By Treatment Type 11.2.3. By Disease Type 11.2.4. By Drug Class 11.2.5. By Route of Administration 11.2.6. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment Type 11.3.3. By Disease Type 11.3.4. By Drug Class 11.3.5. By Route of Administration 11.3.6. By Distribution Channel 11.4. Key Takeaways 12. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. Mexico 12.2.1.2. Brazil 12.2.1.3. Rest of Latin America 12.2.2. By Treatment Type 12.2.3. By Disease Type 12.2.4. By Drug Class 12.2.5. By Route of Administration 12.2.6. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment Type 12.3.3. By Disease Type 12.3.4. By Drug Class 12.3.5. By Route of Administration 12.3.6. By Distribution Channel 12.4. Key Takeaways 13. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 13.2.1. By Country 13.2.1.1. Germany 13.2.1.2. Italy 13.2.1.3. France 13.2.1.4. United Kingdom 13.2.1.5. Spain 13.2.1.6. BENELUX 13.2.1.7. Russia 13.2.1.8. Rest of Europe 13.2.2. By Treatment Type 13.2.3. By Disease Type 13.2.4. By Drug Class 13.2.5. By Route of Administration 13.2.6. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment Type 13.3.3. By Disease Type 13.3.4. By Drug Class 13.3.5. By Route of Administration 13.3.6. By Distribution Channel 13.4. Key Takeaways 14. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Treatment Type 14.2.3. By Disease Type 14.2.4. By Drug Class 14.2.5. By Route of Administration 14.2.6. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment Type 14.3.3. By Disease Type 14.3.4. By Drug Class 14.3.5. By Route of Administration 14.3.6. By Distribution Channel 14.4. Key Takeaways 15. South Asia & Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 15.2.1. By Country 15.2.1.1. India 15.2.1.2. ASEAN 15.2.1.3. Australia and New Zealand 15.2.1.4. Rest of South Asia & Pacific 15.2.2. By Treatment Type 15.2.3. By Disease Type 15.2.4. By Drug Class 15.2.5. By Route of Administration 15.2.6. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Treatment Type 15.3.3. By Disease Type 15.3.4. By Drug Class 15.3.5. By Route of Administration 15.3.6. By Distribution Channel 15.4. Key Takeaways 16. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 16.2.1. By Country 16.2.1.1. GCC Countries 16.2.1.2. Turkey 16.2.1.3. South Africa 16.2.1.4. Rest of Middle East and Africa 16.2.2. By Treatment Type 16.2.3. By Disease Type 16.2.4. By Drug Class 16.2.5. By Route of Administration 16.2.6. By Distribution Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.2. By Treatment Type 16.3.3. By Disease Type 16.3.4. By Drug Class 16.3.5. By Route of Administration 16.3.6. By Distribution Channel 16.4. Key Takeaways 17. Key Countries Market Analysis 17.1. USA 17.1.1. Pricing Analysis 17.1.2. Market Share Analysis, 2021 17.1.2.1. By Treatment Type 17.1.2.2. By Disease Type 17.1.2.3. By Drug Class 17.1.2.4. By Route of Administration 17.1.2.5. By Distribution Channel 17.2. Canada 17.2.1. Pricing Analysis 17.2.2. Market Share Analysis, 2021 17.2.2.1. By Treatment Type 17.2.2.2. By Disease Type 17.2.2.3. By Drug Class 17.2.2.4. By Route of Administration 17.2.2.5. By Distribution Channel 17.3. Mexico 17.3.1. Pricing Analysis 17.3.2. Market Share Analysis, 2021 17.3.2.1. By Treatment Type 17.3.2.2. By Disease Type 17.3.2.3. By Drug Class 17.3.2.4. By Route of Administration 17.3.2.5. By Distribution Channel 17.4. Brazil 17.4.1. Pricing Analysis 17.4.2. Market Share Analysis, 2021 17.4.2.1. By Treatment Type 17.4.2.2. By Disease Type 17.4.2.3. By Drug Class 17.4.2.4. By Route of Administration 17.4.2.5. By Distribution Channel 17.5. Germany 17.5.1. Pricing Analysis 17.5.2. Market Share Analysis, 2021 17.5.2.1. By Treatment Type 17.5.2.2. By Disease Type 17.5.2.3. By Drug Class 17.5.2.4. By Route of Administration 17.5.2.5. By Distribution Channel 17.6. Italy 17.6.1. Pricing Analysis 17.6.2. Market Share Analysis, 2021 17.6.2.1. By Treatment Type 17.6.2.2. By Disease Type 17.6.2.3. By Drug Class 17.6.2.4. By Route of Administration 17.6.2.5. By Distribution Channel 17.7. France 17.7.1. Pricing Analysis 17.7.2. Market Share Analysis, 2021 17.7.2.1. By Treatment Type 17.7.2.2. By Disease Type 17.7.2.3. By Drug Class 17.7.2.4. By Route of Administration 17.7.2.5. By Distribution Channel 17.8. United Kingdom 17.8.1. Pricing Analysis 17.8.2. Market Share Analysis, 2021 17.8.2.1. By Treatment Type 17.8.2.2. By Disease Type 17.8.2.3. By Drug Class 17.8.2.4. By Route of Administration 17.8.2.5. By Distribution Channel 17.9. Spain 17.9.1. Pricing Analysis 17.9.2. Market Share Analysis, 2021 17.9.2.1. By Treatment Type 17.9.2.2. By Disease Type 17.9.2.3. By Drug Class 17.9.2.4. By Route of Administration 17.9.2.5. By Distribution Channel 17.10. BENELUX 17.10.1. Pricing Analysis 17.10.2. Market Share Analysis, 2021 17.10.2.1. By Treatment Type 17.10.2.2. By Disease Type 17.10.2.3. By Drug Class 17.10.2.4. By Route of Administration 17.10.2.5. By Distribution Channel 17.11. Russia 17.11.1. Pricing Analysis 17.11.2. Market Share Analysis, 2021 17.11.2.1. By Treatment Type 17.11.2.2. By Disease Type 17.11.2.3. By Drug Class 17.11.2.4. By Route of Administration 17.11.2.5. By Distribution Channel 17.12. China 17.12.1. Pricing Analysis 17.12.2. Market Share Analysis, 2021 17.12.2.1. By Treatment Type 17.12.2.2. By Disease Type 17.12.2.3. By Drug Class 17.12.2.4. By Route of Administration 17.12.2.5. By Distribution Channel 17.13. Japan 17.13.1. Pricing Analysis 17.13.2. Market Share Analysis, 2021 17.13.2.1. By Treatment Type 17.13.2.2. By Disease Type 17.13.2.3. By Drug Class 17.13.2.4. By Route of Administration 17.13.2.5. By Distribution Channel 17.14. South Korea 17.14.1. Pricing Analysis 17.14.2. Market Share Analysis, 2021 17.14.2.1. By Treatment Type 17.14.2.2. By Disease Type 17.14.2.3. By Drug Class 17.14.2.4. By Route of Administration 17.14.2.5. By Distribution Channel 17.15. India 17.15.1. Pricing Analysis 17.15.2. Market Share Analysis, 2021 17.15.2.1. By Treatment Type 17.15.2.2. By Disease Type 17.15.2.3. By Drug Class 17.15.2.4. By Route of Administration 17.15.2.5. By Distribution Channel 17.16. ASIAN 17.16.1. Pricing Analysis 17.16.2. Market Share Analysis, 2021 17.16.2.1. By Treatment Type 17.16.2.2. By Disease Type 17.16.2.3. By Drug Class 17.16.2.4. By Route of Administration 17.16.2.5. By Distribution Channel 17.17. Australia and New Zealand 17.17.1. Pricing Analysis 17.17.2. Market Share Analysis, 2021 17.17.2.1. By Treatment Type 17.17.2.2. By Disease Type 17.17.2.3. By Drug Class 17.17.2.4. By Route of Administration 17.17.2.5. By Distribution Channel 17.18. GCC Countries 17.18.1. Pricing Analysis 17.18.2. Market Share Analysis, 2021 17.18.2.1. By Treatment Type 17.18.2.2. By Disease Type 17.18.2.3. By Drug Class 17.18.2.4. By Route of Administration 17.18.2.5. By Distribution Channel 17.19. Turkey 17.19.1. Pricing Analysis 17.19.2. Market Share Analysis, 2021 17.19.2.1. By Treatment Type 17.19.2.2. By Disease Type 17.19.2.3. By Drug Class 17.19.2.4. By Route of Administration 17.19.2.5. By Distribution Channel 17.20. South Africa 17.20.1. Pricing Analysis 17.20.2. Market Share Analysis, 2021 17.20.2.1. By Treatment Type 17.20.2.2. By Disease Type 17.20.2.3. By Drug Class 17.20.2.4. By Route of Administration 17.20.2.5. By Distribution Channel 18. Market Structure Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Market Share Analysis of Top Players 18.3.1. By Regional 18.3.2. By Treatment Type 18.3.3. By Disease Type 18.3.4. By Drug Class 18.3.5. By Route of Administration 18.3.6. By Distribution Channel 19. Competition Analysis 19.1. Competition Deep Dive 19.1.1. F. Hoffmann-La Roche Ltd 19.1.1.1. Overview 19.1.1.2. Product Portfolio 19.1.1.3. Profitability by Market Segments 19.1.1.4. Sales Footprint 19.1.1.5. Strategy Overview 19.1.1.5.1. Marketing Strategy 19.1.1.5.2. Product Strategy 19.1.1.5.3. Channel Strategy 19.1.2. GlaxoSmithKline plc. 19.1.2.1. Overview 19.1.2.2. Product Portfolio 19.1.2.3. Profitability by Market Segments 19.1.2.4. Sales Footprint 19.1.2.5. Strategy Overview 19.1.2.5.1. Marketing Strategy 19.1.2.5.2. Product Strategy 19.1.2.5.3. Channel Strategy 19.1.3. Merck & Co. 19.1.3.1. Overview 19.1.3.2. Product Portfolio 19.1.3.3. Profitability by Market Segments 19.1.3.4. Sales Footprint 19.1.3.5. Strategy Overview 19.1.3.5.1. Marketing Strategy 19.1.3.5.2. Product Strategy 19.1.3.5.3. Channel Strategy 19.1.4. Agennix AG 19.1.4.1. Overview 19.1.4.2. Product Portfolio 19.1.4.3. Profitability by Market Segments 19.1.4.4. Sales Footprint 19.1.4.5. Strategy Overview 19.1.4.5.1. Marketing Strategy 19.1.4.5.2. Product Strategy 19.1.4.5.3. Channel Strategy 19.1.5. Boehringer Ingelheim GmbH 19.1.5.1. Overview 19.1.5.2. Product Portfolio 19.1.5.3. Profitability by Market Segments 19.1.5.4. Sales Footprint 19.1.5.5. Strategy Overview 19.1.5.5.1. Marketing Strategy 19.1.5.5.2. Product Strategy 19.1.5.5.3. Channel Strategy 19.1.6. Sanofi-Aventis 19.1.6.1. Overview 19.1.6.2. Product Portfolio 19.1.6.3. Profitability by Market Segments 19.1.6.4. Sales Footprint 19.1.6.5. Strategy Overview 19.1.6.5.1. Marketing Strategy 19.1.6.5.2. Product Strategy 19.1.6.5.3. Channel Strategy 19.1.7. Eli Lilly and Company 19.1.7.1. Overview 19.1.7.2. Product Portfolio 19.1.7.3. Profitability by Market Segments 19.1.7.4. Sales Footprint 19.1.7.5. Strategy Overview 19.1.7.5.1. Marketing Strategy 19.1.7.5.2. Product Strategy 19.1.7.5.3. Channel Strategy 19.1.8. Celgene Corporation 19.1.8.1. Overview 19.1.8.2. Product Portfolio 19.1.8.3. Profitability by Market Segments 19.1.8.4. Sales Footprint 19.1.8.5. Strategy Overview 19.1.8.5.1. Marketing Strategy 19.1.8.5.2. Product Strategy 19.1.8.5.3. Channel Strategy 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Lung Cancer Therapeutics Market
